Skip to content
Biodatica
Start free

Acrivon Therapeutics

Mobile, Alabama

OncologyPhase IIListed · ACRV

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

4w agoTrial registeredJun 17, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Aug 29, 2022

    Endometrial Adenocarcinoma · RECRUITING · sponsor: Acrivon Therapeutics · A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

    ClinicalTrials.gov · NCT05548296 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jan 2, 2020

    Endometrial Cancer · ACTIVE_NOT_RECRUITING · sponsor: Dana-Farber Cancer Institute · A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

    ClinicalTrials.gov · NCT03835819 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Aug 25, 2016

    Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    ClinicalTrials.gov · NCT02595892 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources